贝伐单抗抑制角膜新生血管的实验研究

目的评价贝伐单抗（avastin）局部应用对小鼠角膜新生血管（CNV）的抑制作用。方法通过碱烧伤建立CNV模型，将30只Balb／c小鼠随机分成5组，A组贝伐单抗1mg／mL每日点眼2次；B组贝伐单抗3mg／mL每日点眼2次；C组贝伐单抗5mg／mL每日点眼2次；D组0．1％地塞米松每日点眼2次；E组生理盐水每日点眼2次。分别于术后3、7、14d观察CNV情况并拍照。术后第14天，处死全部小鼠，行CNV内皮细胞荧光标记，计算CNV所占全角膜面积的比例。结果各组CNV面积为A组（37．11±3．17）％、B组（29．75±3．56）％、C组（18．76±2．55）％、D组（20．91±2．75）％，E组（41．65±2．11）％。各组小鼠CNV面积依次为c组〈D组〈B组〈A组〈E组，C组同A、B、E组比较差异均有统计学意义（P〈0．01），c组与D组比较差异无统计学意义（P=0．694）。结论局部应用贝伐单抗对小鼠角膜化学烧伤后的CNV有抑制作用。

Effect of topical bevacizumab on experimental corneal neovascularization in mouse

Objective The inhibitory effects of avastin on new blood vessels in nonproliferation diabetic retinopathy, age-related macular degeneration and neovascular glaucoma have been demonstrated. But only seldom report of avastin on corneal neovascularization(CNV) was seen. Present study was to evaluate the effect of topical bevacizumab (avastin) on experimental corneal neovascularization in mice. Methods Thirty eyes of 30 Balb/c mice were chemically cauterized by applying a 2 mm-diameter filter paper soaked 1 mol/L NaOH solution at the central cornea for 40 s. All animals were randomly assigned to five groups, including 1 mg/mL, 3 mg/mL and 5 mg/mL bevacizumab eye drops group respectively, 1 mg/mL dexamethasone sodium phosphate eye drops group (positive control) and normal saline solution group (negative control) . The drug was topically utilized twice per day. CNV was examined under the slim lamp on the 3rd, 7th and 14th day after alkali burn. Animals were killed on the 14th day after alkali burn. Area of CNV was calculated in terms of pixels on digital photographs. The use of animals followed the Regulations for the Administration of Affair Concerning Experimental Animals by State Science and Technology Commission. Results No significant difference was found in the grade of corneal injury among five groups (F = 0. 201, P = 0. 935). The area of neovascularization at the cornea surface was (37.11 ±3.17)% in 1 mg/mL bevacizumab group, (29.75 ±3.56)% in 3 mg/mL bevacizumab group, (18. 76 ± 2. 55) % in 5 mg/mL bevacizumab group, (20. 91 ± 2. 75) % in dexamethasone group and (41. 65 ±2. 11)% in normal saline group, showing a significant difference among groups(F = 71. 687, P =0. 000) with the further comparative decline in 5 mg/mL bevacizumab group compared with other groups (P ＜ 0. 01) . Conclusion The topical use of bevacizumab (avastin) inhibits alkali burn-induced CNV in mice.